Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
In Vivo. 2021 Mar-Apr;35(2):1247-1252. doi: 10.21873/invivo.12375.
BACKGROUND/AIM: Vintage hormone therapy for non-metastatic castration-resistant prostate cancer (nmCRPC) is not recommended under the current guidelines, but is widely practiced in Japan. This study assessed effectiveness of vintage hormone therapy as alternative androgen deprivation therapy (AADT) for treatment of nmCRPC.
In this retrospective study we examined patients with nmCRPC that received vintage hormone therapy as AADT between 1999 and 2018.
Of 53 patients with nmCRPC, 25 patients (47.2%) had stage 1 nodal disease (N1) at diagnosis of nmCRPC. Prostate specific antigen (PSA) reduction rate≥30% was observed in 32 patients (72.7%). The median PSA nadir was 0.7, and the duration of the response was 14.3 months. The median metastasis-free survival (MFS) for the entire patient population was 62.2 months, and the median overall survival (OS) was not reached. In the multivariate analysis, the duration of response in AADT>18 months was a predictor of prolonged OS.
There is a certain number of nmCRPC patients who respond well to vintage hormone therapy as AADT. Further studies are expected to differentiate such cases.
背景/目的：目前的指南不建议将传统激素疗法用于非转移性去势抵抗性前列腺癌（nmCRPC），但在日本广泛应用。本研究评估了传统激素疗法作为替代雄激素剥夺疗法（AADT）治疗 nmCRPC 的有效性。
在这项回顾性研究中，我们检查了 1999 年至 2018 年间接受传统激素疗法作为 AADT 的 nmCRPC 患者。
53 例 nmCRPC 患者中，25 例（47.2%）在诊断为 nmCRPC 时存在 1 期淋巴结疾病（N1）。32 例（72.7%）患者的前列腺特异性抗原（PSA）下降率≥30%。PSA 最低值为 0.7，反应持续时间为 14.3 个月。全组患者的无转移生存（MFS）中位数为 62.2 个月，总生存（OS）未达到。多变量分析显示，AADT 中反应持续时间>18 个月是 OS 延长的预测因素。
有一定数量的 nmCRPC 患者对传统激素疗法作为 AADT 反应良好。需要进一步研究以区分这些情况。
